JACC:残余炎症可增加PCI术后患者不良心脑血管事件风险

2019-05-20 不详 MedSci原创

目前,对于残余炎症风险(RIR)对接受冠脉介入治疗(PCI)且基线低密度脂蛋白胆固醇(LDL-C)≤70mg/dl患者的影响尚不清楚。本研究的目的旨在评估PCI术后高RIR的发生率和影响。本研究纳入了2009-2016年基线LDL-C≤70mg/dl并进行了高敏C反应蛋白(hsCRP)评估的PCI患者,高RIR定义为hsCRP >2 mg/l。患者根据RIR状态分为持续性低RIR组、RIR减

目前,对于残余炎症风险(RIR)对接受冠脉介入治疗(PCI)且基线低密度脂蛋白胆固醇(LDL-C)≤70mg/dl患者的影响尚不清楚。本研究的目的旨在评估PCI术后高RIR的发生率和影响。

本研究纳入了2009-2016年基线LDL-C≤70mg/dl并进行了高敏C反应蛋白(hsCRP)评估的PCI患者,高RIR定义为hsCRP >2 mg/l。患者根据RIR状态分为持续性低RIR组、RIR减弱组、RIR增高组和持续性高RIR组,主要终点事件是主要不良心脑血管事件(MACCE),包括死亡、心梗或卒中。最终共纳入3013名患者,持续性低RIR组、RIR减弱组、RIR增高组和持续性高RIR组分别有1225 (41.7%)、414 (13.7%)、346 (11.5%)和1028 (34.1%)名。这四组之间,MACCE发生风险呈逐步增高趋势( p < 0.001)。经混杂因素调整后,持续性高RIR与MACCE的发生呈强相关(HR:2.10; 95% cl: 1.45-3.02; p < 0.001)。

研究结果显示,在接受冠脉介入治疗且基线低密度脂蛋白胆固醇≤70mg/dl患者中,残余炎症风险与不良心脑血管事件是发生呈明显相关性。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1234152, encodeId=9ac61234152b9, content=<a href='/topic/show?id=cb288509131' target=_blank style='color:#2F92EE;'>#脑血管事件#</a><a href='/topic/show?id=acea1045612f' target=_blank style='color:#2F92EE;'>#残余风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85091, encryptionId=cb288509131, topicName=脑血管事件), TopicDto(id=104561, encryptionId=acea1045612f, topicName=残余风险)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Jul 23 03:26:14 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643611, encodeId=f62916436116f, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 19 10:12:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854390, encodeId=8d85185439030, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Mar 01 06:12:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633845, encodeId=40ca163384561, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Nov 19 10:12:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326211, encodeId=2b6b1326211ce, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486437, encodeId=022f148643ef4, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581008, encodeId=d39a1581008c3, content=<a href='/topic/show?id=03d051e14e5' target=_blank style='color:#2F92EE;'>#心脑血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51714, encryptionId=03d051e14e5, topicName=心脑血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aec16671813, createdName=1508842480_96220442, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1234152, encodeId=9ac61234152b9, content=<a href='/topic/show?id=cb288509131' target=_blank style='color:#2F92EE;'>#脑血管事件#</a><a href='/topic/show?id=acea1045612f' target=_blank style='color:#2F92EE;'>#残余风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85091, encryptionId=cb288509131, topicName=脑血管事件), TopicDto(id=104561, encryptionId=acea1045612f, topicName=残余风险)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Jul 23 03:26:14 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643611, encodeId=f62916436116f, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 19 10:12:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854390, encodeId=8d85185439030, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Mar 01 06:12:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633845, encodeId=40ca163384561, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Nov 19 10:12:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326211, encodeId=2b6b1326211ce, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486437, encodeId=022f148643ef4, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581008, encodeId=d39a1581008c3, content=<a href='/topic/show?id=03d051e14e5' target=_blank style='color:#2F92EE;'>#心脑血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51714, encryptionId=03d051e14e5, topicName=心脑血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aec16671813, createdName=1508842480_96220442, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1234152, encodeId=9ac61234152b9, content=<a href='/topic/show?id=cb288509131' target=_blank style='color:#2F92EE;'>#脑血管事件#</a><a href='/topic/show?id=acea1045612f' target=_blank style='color:#2F92EE;'>#残余风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85091, encryptionId=cb288509131, topicName=脑血管事件), TopicDto(id=104561, encryptionId=acea1045612f, topicName=残余风险)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Jul 23 03:26:14 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643611, encodeId=f62916436116f, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 19 10:12:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854390, encodeId=8d85185439030, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Mar 01 06:12:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633845, encodeId=40ca163384561, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Nov 19 10:12:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326211, encodeId=2b6b1326211ce, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486437, encodeId=022f148643ef4, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581008, encodeId=d39a1581008c3, content=<a href='/topic/show?id=03d051e14e5' target=_blank style='color:#2F92EE;'>#心脑血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51714, encryptionId=03d051e14e5, topicName=心脑血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aec16671813, createdName=1508842480_96220442, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2020-03-01 hbwxf
  4. [GetPortalCommentsPageByObjectIdResponse(id=1234152, encodeId=9ac61234152b9, content=<a href='/topic/show?id=cb288509131' target=_blank style='color:#2F92EE;'>#脑血管事件#</a><a href='/topic/show?id=acea1045612f' target=_blank style='color:#2F92EE;'>#残余风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85091, encryptionId=cb288509131, topicName=脑血管事件), TopicDto(id=104561, encryptionId=acea1045612f, topicName=残余风险)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Jul 23 03:26:14 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643611, encodeId=f62916436116f, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 19 10:12:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854390, encodeId=8d85185439030, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Mar 01 06:12:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633845, encodeId=40ca163384561, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Nov 19 10:12:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326211, encodeId=2b6b1326211ce, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486437, encodeId=022f148643ef4, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581008, encodeId=d39a1581008c3, content=<a href='/topic/show?id=03d051e14e5' target=_blank style='color:#2F92EE;'>#心脑血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51714, encryptionId=03d051e14e5, topicName=心脑血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aec16671813, createdName=1508842480_96220442, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2019-11-19 zxl736
  5. [GetPortalCommentsPageByObjectIdResponse(id=1234152, encodeId=9ac61234152b9, content=<a href='/topic/show?id=cb288509131' target=_blank style='color:#2F92EE;'>#脑血管事件#</a><a href='/topic/show?id=acea1045612f' target=_blank style='color:#2F92EE;'>#残余风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85091, encryptionId=cb288509131, topicName=脑血管事件), TopicDto(id=104561, encryptionId=acea1045612f, topicName=残余风险)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Jul 23 03:26:14 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643611, encodeId=f62916436116f, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 19 10:12:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854390, encodeId=8d85185439030, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Mar 01 06:12:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633845, encodeId=40ca163384561, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Nov 19 10:12:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326211, encodeId=2b6b1326211ce, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486437, encodeId=022f148643ef4, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581008, encodeId=d39a1581008c3, content=<a href='/topic/show?id=03d051e14e5' target=_blank style='color:#2F92EE;'>#心脑血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51714, encryptionId=03d051e14e5, topicName=心脑血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aec16671813, createdName=1508842480_96220442, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1234152, encodeId=9ac61234152b9, content=<a href='/topic/show?id=cb288509131' target=_blank style='color:#2F92EE;'>#脑血管事件#</a><a href='/topic/show?id=acea1045612f' target=_blank style='color:#2F92EE;'>#残余风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85091, encryptionId=cb288509131, topicName=脑血管事件), TopicDto(id=104561, encryptionId=acea1045612f, topicName=残余风险)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Jul 23 03:26:14 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643611, encodeId=f62916436116f, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 19 10:12:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854390, encodeId=8d85185439030, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Mar 01 06:12:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633845, encodeId=40ca163384561, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Nov 19 10:12:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326211, encodeId=2b6b1326211ce, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486437, encodeId=022f148643ef4, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581008, encodeId=d39a1581008c3, content=<a href='/topic/show?id=03d051e14e5' target=_blank style='color:#2F92EE;'>#心脑血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51714, encryptionId=03d051e14e5, topicName=心脑血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aec16671813, createdName=1508842480_96220442, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1234152, encodeId=9ac61234152b9, content=<a href='/topic/show?id=cb288509131' target=_blank style='color:#2F92EE;'>#脑血管事件#</a><a href='/topic/show?id=acea1045612f' target=_blank style='color:#2F92EE;'>#残余风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85091, encryptionId=cb288509131, topicName=脑血管事件), TopicDto(id=104561, encryptionId=acea1045612f, topicName=残余风险)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Jul 23 03:26:14 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643611, encodeId=f62916436116f, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Thu Mar 19 10:12:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854390, encodeId=8d85185439030, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Mar 01 06:12:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633845, encodeId=40ca163384561, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Tue Nov 19 10:12:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326211, encodeId=2b6b1326211ce, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486437, encodeId=022f148643ef4, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581008, encodeId=d39a1581008c3, content=<a href='/topic/show?id=03d051e14e5' target=_blank style='color:#2F92EE;'>#心脑血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51714, encryptionId=03d051e14e5, topicName=心脑血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aec16671813, createdName=1508842480_96220442, createdTime=Wed May 22 05:12:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]

相关资讯

JACC:钙离子通道阻滞剂可改善桡动脉冠脉搭桥患者预后

本研究的目的旨在评估慢性钙离子通道阻滞剂(CCB)对桡动脉(RA)冠脉搭桥中期临床预后和血管生成的影响。本研究纳入了732名RA冠脉搭桥患者,其中502名接受了CCB治疗,经过平均60个月时间的随访,CCB治疗组和非CCB治疗组患者的第36、72和108个月的累积主要不良心血管事件(MACE)发生率分别是 3.7% vs. 9.3%, 13.4% vs. 17.6%, 16.8% vs. 20.5

罗沙司他全球III期临床研究证实其心血管安全性

近日,阿斯利康公布其罗沙司他全球III期临床研究心血管(CV)安全性汇总分析结果。罗沙司他是全球首个低氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI),也是首个在中国获批上市的肾性贫血口服新药,已于2018年12月获得国家药品监督管理局(NMPA)的上市批准,用于慢性肾脏病透析患者的贫血治疗。本次试验评估了罗沙司他在非透析(NDD)、初始非稳定透析(ID)和稳定透析的慢性肾脏病(CKD)患者人群中贫

JACC:一种可预测10年心衰风险模型的开发

目前尚无心衰的一级预防策略,且缺少心衰的风险预测工具。本研究的目的旨在推导出发展为心衰的10年风险方程。本研究纳入了1985-2000年30-79岁的无心血管疾病的参与者作为合并队列(PC),随机分为两组进行推导和内部验证,并在2个另外的队列中对模型方程进行验证。最终共有11771名对象纳入PC,女性占58%,黑种人占22%,平均年龄52±12岁,有1339名患有心衰。心衰风险的预测模型中包括年龄

盘点:JACC五月第二期研究一览

1.利伐沙班联合阿司匹林可减少肾功能不全患者的不良事件风险

JACC:半乳凝素-3是心梗患者死亡和心衰的独立预测因子

半乳凝素-3(Gal-3)与心脏纤维化呈相关性,但其与心梗后不良事件的相关性尚不清楚,本研究的目的旨在评估Gal-3在心梗中的预测价值。本研究共纳入了1342名心梗患者(平均年龄67.1岁,男性占61.3%,78.8%为非ST段抬高型心梗),Gal-3水平升高的患者往往更年长,且并发症更多。经过平均5.4年时间的随访,484名患者死亡,368名患者发展为心衰。经年龄、性别、并发症和肌钙蛋白等因素调